Advanced Prostate Cancer

Treatment approaches covered

- Hormonal therapy
- Chemotherapy
- Immunotherapy
- Radiopharmaceuticals
- Radiation

Interventions for complications of local progression

Details

1. Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
2. Recorded via the Eastern Cooperative Oncology Group (ECOG) score
3. Includes pain-related quality of life and need for pain medication
4. Includes urinary incontinence, urinary frequency, urinary obstruction, urinary irritation, and bowel irritation
5. Includes hormonal symptoms
6. Recommended to track via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
7. Recommended to track via the Expanded Prostate Cancer Index Composite (EPIC 26 version preferred)
8. Includes symptomatic skeletal related event, time to metastasis, castration resistant disease, and procedures needed for local progression

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit https://connect.ichom.org/patient-centered-outcome-measures/advanced-prostate-cancer/

© 2023 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more Sets of Patient Outcomes Measures. Version 4.1.0 Revised: February 2023
Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsor

The Working Group

Australia
Ian Davis | Monash University; Eastern Health Clinical School
Sue Evans | Monash University
Ian Roos* | Cancer Action Victoria

Belgium
Louis Denis* | Oncology Center Antwerp, US TOO Belgium
Bertrand Tombal | Cliniques Universitaires Saint Luc, Université Catholique de Louvain

Canada
Neil Fleshner | University of Toronto
Andrew Matthew | University of Toronto

France
Alberto Bossi | Gustave Roussy Cancer Institute

Germany
Thomas Steuber | University Hospital Hamburg-Eppendorf

Ireland
Ray McDermott | St. Vincent’s University Hospital

Netherlands
Theo de Reijke | Academic Medical Center Amsterdam

United Kingdom
Heather Payne | University College Hospitals London

United States
Janet Abraham | Dana-Farber Cancer Institute
Ethan Basch | University of North Carolina at Chapel Hill
Justin Bekelman | University of Pennsylvania

Jean-Paul van Basten | Canisius Wilhelmina Hospital
Koos van der Hoeven | Leiden University Medical Center

Donna Berry | Dana-Farber Cancer Institute
Daniel George | Duke University Medical Center
Jim Kiefert* | US TOO
Daniel Lin | University of Washington
Alicia Morgans | Vanderbilt University Medical Center
David Penson | Vanderbilt University Medical Center
Deborah Schrag | Dana-Farber Cancer Institute

*Patient representative